The development prospect of Chinese herbal medicine for multinational enterprises

Recently, Amway said it would invest in the establishment of a plant research center in China, focusing on the research and pilot cultivation of traditional Chinese herbal medicines This is Amway's further investment in China's R & D after the establishment of China's R & D center in 2004 The Amway (China) plant research center will focus on the study of a variety of traditional Chinese herbal medicines within the scope of traditional Chinese medicine After the completion of the project, it will become the fifth plant related research institution in the world after the United States, Brazil and Mexico Guo Fanli, a researcher in the pharmaceutical industry at CIC, said Amway would invest in establishing a plant research center in China this time, indicating that it is optimistic about the prospect of Chinese herbal medicine In addition to Amway, global well-known enterprises like Unilever have begun to invest in Chinese herbal medicine research The attention of multinational enterprises to Chinese herbal medicine has increased substantially since the new medical reform I believe that these growth has a great relationship with the support of the state for the Chinese medicine industry in recent years Guo Fanli pointed out that for a long time before the new medical reform, multinational enterprises always had an exclusive attitude towards Chinese herbal medicine, because the foreign understanding of Chinese herbal medicine remained on the "all inclusive treatment" Foreign developed countries attach great importance to life and health, especially to the safety of drugs They can't accept Chinese herbal medicines without pathological effects and adverse reactions into the daily treatment of diseases But now, there are some changes in their attitude According to the data of CIC Consulting Industry Research Center, from January to June 2010, the import and export volume of plant extracts in China reached 450 million US dollars, an increase of 19.6% year on year, and the total import and export volume continued to maintain a stable growth, an increase of 10.2% year on year Among them, the export volume of plant extracts was US $380 million, an increase of 19.3% over the previous year, accounting for 41.6% of the export volume of traditional Chinese medicine products, and the export volume was 23000 tons, an increase of 13.0% over the previous year, with the average export price increasing by 5.6% over the previous year Zhang Yanlin, research director of CIC, pointed out that foreign developed countries pay special attention to health care, and they have a special preference for green and healthy herbal medicines Because of this, China's export of plant extracts keeps a steady growth every year, and at the same time, it also enhances the understanding of Chinese herbal medicine by foreign consumers It is the foreign multinational groups that have taken a good look at the broad development prospect of plant extracts in China that have stepped up the establishment of a series of R & D centers in China According to the investment analysis and prospect forecast report of China Pharmaceutical Industry 2010-2015 issued by CIC consultant, although plant extract accounts for nearly half of the export share of Chinese herbal products, it is also the main driving force to promote the export of Chinese herbal products, there are still serious homogenization and low access threshold problems in China's plant extract industry Therefore, we need to establish a perfect quality standard system for the plant extract industry in order to ensure the healthy and stable development of the plant extract industry in China.